IOVS Proceedings of the National Academy of Sciences
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2004;45:2413-2419.)
© 2004 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.03-1001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pan, H.
Right arrow Articles by Grant, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pan, H.
Right arrow Articles by Grant, M. B.

Molecular Targeting of Antiangiogenic Factor 16K hPRL Inhibits Oxygen-Induced Retinopathy in Mice

Hao Pan,1 Ngoc-Quynh-Nhu Nguyen,2 Hiroshi Yoshida,3 Frauke Bentzien,3 Lynn C. Shaw,1 Francoise Rentier-Delrue,2 Joseph A. Martial,2 Richard Weiner,3 Ingrid Struman,2 and Maria B. Grant1

1From the Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida; 2Laboratoire de Biologie Moléculaire et de Génie Génétique, Université de Liège, Liège, Belgium; and 3Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco, San Francisco, California.

PURPOSE. To examine the ability and mechanism of the 16 kDa N-terminal fragment of human prolactin (16K hPRL) in the inhibition of abnormal retinal neovascularization.

METHODS. The 16K hPRL-encoding sequence was inserted into an adenoviral vector (16K-Ad). Western blot analysis verified the expression of 16K hPRL and inhibition of proliferation, confirming functional activity of the 16K hPRL in virus-infected adult bovine aortic endothelial (ABAE) cells. 16K hPRL inhibited retinal neovascularization in a mouse model of oxygen-induced retinopathy. The ability of recombinant 16K hPRL expressed in E. coli (r16K hPRL) was compared to that of endostatin in inducing apoptosis of cultured human retinal endothelial cells (HREC).

RESULTS. 16K was expressed in virus-infected ABAE cells and resulted in a dose-dependent inhibition of cell proliferation. Eyes injected with 16K-Ad showed a reduction in preretinal neovascularization of 82.3 ± 9.3% (P < 0.00001) when compared to uninjected controls. r16K hPRL was 100 times more potent than endostatin in inducing apoptosis in HRECs.

CONCLUSIONS. Intravitreal administration of 16K hPRL inhibited neovascularization in the mouse model of oxygen-induced retinopathy. 16K hPRL stimulated apoptosis in HRECs and inhibited cell proliferation in ABAE cells. These results suggested a potential therapeutic role for 16K hPRL in the treatment of proliferative retinopathies.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera
Vasoinhibins: novel inhibitors of ocular angiogenesis
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E772 - E778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. P. Tabruyn, C. Sabatel, N.-Q.-N. Nguyen, C. Verhaeghe, K. Castermans, L. Malvaux, A. W. Griffioen, J. A. Martial, and I. Struman
The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-{kappa}B Activation
Mol. Endocrinol., June 1, 2007; 21(6): 1422 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N.-Q.-N. Nguyen, S. P. Tabruyn, L. Lins, M. Lion, A. M. Cornet, F. Lair, F. Rentier-Delrue, R. Brasseur, J. A. Martial, and I. Struman
Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis
PNAS, September 26, 2006; 103(39): 14319 - 14324.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp
Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin
J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al.
16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway
Cancer Res., September 1, 2005; 65(17): 7984 - 7992.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. Aranda, J. C. Rivera, M. C. Jeziorski, J. Riesgo-Escovar, G. Nava, F. Lopez-Barrera, H. Quiroz-Mercado, P. Berger, G. Martinez de la Escalera, and C. Clapp
Prolactins Are Natural Inhibitors of Angiogenesis in the Retina
Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2947 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. P. Tabruyn, N.-Q.-N. Nguyen, A. M. Cornet, J. A. Martial, and I. Struman
The Antiangiogenic Factor, 16-kDa Human Prolactin, Induces Endothelial Cell Cycle Arrest by Acting at Both the G0-G1 and the G2-M Phases
Mol. Endocrinol., July 1, 2005; 19(7): 1932 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nyberg, L. Xie, and R. Kalluri
Endogenous Inhibitors of Angiogenesis
Cancer Res., May 15, 2005; 65(10): 3967 - 3979.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association for Research in Vision and Ophthalmology